Rare diseases: FDA proposes new system to therapy approvals

• by Matthew Perrone

• February 23, 2026

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

• by Meg Barbor

• April 9, 2026

• 2 min

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

• by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

• May 5, 2026

Cutaneous Rhabdomyosarcoma May Mask Melanoma

Molecular and epigenetic profiling suggested most tumors in a rare cutaneous sarcoma cohort were better classified as transdifferentiated melanoma.

• by Andrea Surnit

• April 28, 2026

• 3 min